The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Mixed, IAG Drops Despite Guidance Upgraded

Fri, 30th Oct 2015 08:31

LONDON (Alliance News) - Stocks in London opened mixed Friday, with IAG as the worst blue-chip performer even though it reported a rise in operating profit in the third quarter and upgraded its profit guidance for 2015.

The FTSE 100 index opened down 0.1% at 6,389.83 points, the FTSE 250 was flat at 17,108.13, while the AIM All-Share was up 0.1% at 741.28. In Europe, the CAC 40 in Paris was up up 0.5% and the DAX 30 in Frankfurt was up 0.4%.

International Consolidated Airlines Group, which on Thursday approved its first dividend payment since it was created in 2011, said its operating profit in the third quarter to the end of September was EUR1.25 billion, up from EUR900.0 million a year earlier and still up to EUR1.21 billion when excluding the contribution from Aer Lingus Group, the Irish flag carrier IAG acquired this year.

For the nine months to the end of September, operating profit for the group was up to EUR1.77 billion from EUR1.05 billion a year earlier, a 69% rise.

The strong results in the quarter meant IAG has upgraded its operating profit guidance for the full year to EUR2.25 billion to EUR2.30 billion, a firmer target than the previous guidance for profit to be in excess of EUR2.20 billion. The new guidance also excludes any contribution from Aer Lingus.

Shares in the British Airways and Iberia owner were down 4.6% at the open.

Meanwhile, Royal Bank of Scotland Group was down 1.1%. It reported improved third-quarter net profit, as it booked a big gain on the loss of control of Citizens, the US retail bank it is selling, but warned that the costs of restructuring and addressing past conduct and litigation are not about to go away.

The bank said it made a GBP952 million net profit in the three months to September 30, compared with GBP896 million in the corresponding quarter the prior year. That included a GBP1.15 billion gain on the loss of control of Citizens, and the bank also confirmed that it is set to sell its remaining 20.9% stake in that bank.

Citizens Financial Group on Thursday said that RBS is now expected to exit its remaining 20.9% stake in the US retail bank. According to Citizens, RBS has launched a registered underwritten public offering to sell all of its remaining 110.5 million shares in the bank. RBS had previously set out plans to divest the rest of its stake by the end of 2015.

RBS peer Barclays was down 0.9% after several price target cuts from JPMorgan, Goldman Sachs, Exane BNP and Societe Generale. The bank closed Thursday as the biggest faller after it missed market expectations and cut guidance for 2016, as its adjusted pretax profit fell in the third quarter.

In the FTSE 250, Vectura Group is the best performer, up 4.7%, after it said it has secured two milestone payments following an approval of an inhaler in the US and after hitting a development milestone in Europe.

It said the US Food and Drug Administration has approved the dual combination Utibron Neohaler and Seebri Neohaler products for the long-term treatment of patients with chronic obstructive pulmonary disease. The approval has triggered a USD22.5 million milestone payment to Vectura from Swiss pharmaceuticals giant Novartis, Vectura's partner on the product.

Separately, the group has been paid a USD750,000 cash milestone after a further development milestone was hit for its VR632 therapy in the European Union. VR632 is an asthma and COPD inhaled treatment therapy which users Vectura's dry powder inhaler and formulation technology.

Outside company news, the Bank of Japan said that its Monetary Policy Board, governed by Haruhiko Kuroda, decided by an 8-1 majority vote to keep its target of raising the monetary base at an annual pace of about JPY80 trillion. The bank also maintained its asset purchase program unchanged.

Some economists had hoped that the Bank of Japan would announce additional stimulus, as the domestic economy is still struggling with deflation and a fits-and-starts recovery. The yen firmed up in reaction to the decision and is currently trading at the upper 120-range against the dollar.

"The market response suggests markets content with the status quo and especially the option for more QE later as well as the BoJ's confidence in a growth turnaround," said Accendo Markets analyst Michael van Dulken.

"Not dissimilar to the hawkish Fed statement mid-week seeing the positive outlook on growth outweighing the prospect of higher rates on the horizon. Markets still like cheap money, but may be coming round to a return to preference for actual growth," van Dulken added.

The Japanese Nikkei 225 index closed Friday up 0.8%. In China, the Shanghai Composite finished down 0.1%, while the Hang Seng in Hong Kong ended down 0.8%.

Wall Street ended mostly lower Thursday, with the DJIA down 0.1%, the S&P 500 flat and the Nasdaq Composite down 0.4%.

Growth in US economic activity slowed in the third quarter, according to a report released by the Commerce Department on Thursday. The report said annualised real gross domestic product rose by 1.5% in the third quarter compared to the 3.9% jump seen in the second quarter. Economists had expected a 1.7% increase.

In the economic calendar Friday, eurozone inflation and unemployment are at 1000 GMT. In the US, personal consumption data is at 1230 GMT, the Chicago purchasing managers' index is at 1345 GMT, and the Reuters/Michigan consumer sentiment index is at 1400 GMT.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
1 May 2020 14:30

Vectura upbeat on EMA nod for 'Enerzair Breezhaler'

(Sharecast News) - Inhalation contract manufacturer Vectura Group noted an announcement from Novartis on Friday, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of 'Enerzair Breezhaler'.

Read more
23 Mar 2020 09:43

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

Read more
17 Mar 2020 12:31

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Read more
10 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
27 Jan 2020 09:36

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
13 Jan 2020 09:19

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Read more
13 Jan 2020 08:25

Vectura sees FY revenues and earnings 'at least' in line with expectations

(Sharecast News) - Pharmaceuticals company Vectura said on Monday that its base business had continued to perform well in 2019.

Read more
27 Nov 2019 08:26

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

Read more
29 Oct 2019 09:41

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Read more
18 Oct 2019 16:06

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
4 Oct 2019 17:31

UPDATE 1-Vectura, Sandoz win ruling on inhaler packaging case against GSK

(Adds comment from GSK spokesman)Oct 4 (Reuters) - Vectura Group said on Friday a British court had ruled in its favour on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.Vectura said the court dismissed all G...

Read more
4 Oct 2019 14:24

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

Read more
3 Oct 2019 16:04

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.